Pulse Biosciences, Inc.

NASDAQ:PLSE

Medical - Instruments & Supplies

Healthcare
$45.83 +3.83%

+$0.97 today

Market cap
$3.37B
Beta
1.66
P/E (TTM)
-24.0
EPS (TTM)
-$1.10
52W Low $12.56High $28.53

Volume 0.33M

Average 0.31M

PLSE Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Pulse Biosciences, Inc.NASDAQ: PLSE

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin growth accelerates

Q2 FY2026 selling, general & admin of $8.46M rose 3.3% year over year, ahead of the -1.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 28.3% from the prior quarter. Over 3 fiscal years it compounded at +7.2% a year.

Context

  • Selling, general & admin amounted to 9151.1% of revenue in FY2025.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 4 analysts of $57.36M (+79.1%) for the fiscal year ending Dec 2026, a step up from the +33.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$8.46M+28.3% QoQ
Last fiscal yearDec 2025
$32.03M+33.9% YoY
LTMJun 2026
$30.9M-1.8% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.3%+83.2%+79.9 pp
1 year+33.9%+79.1%+45.2 pp
3-year CAGR+7.2%+129.7%+122.5 pp
5-year CAGR+147.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
32.03M USD
Year-over-year change
+33.9%
4-year CAGR
-1.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How PLSE compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -1.8% is the 7th highest of 11, against a peer median of +10.3%.
  • Selling, general & admin amounts to 2607.6% of revenue for PLSE, versus a peer median of 95.4%.
PLSE Competitors
Selling, General & Admin for PLSE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVCRNovoCure LimitedLTM Mar 2026$461.38M USD+6.1%+10.9%68.4%
OPKOPKO Health, Inc.LTM Mar 2026$212.52M USD-27.5%-15.7%36.6%
STAASTAAR Surgical CompanyLTM Apr 2026$177.31M USD-11.1%+9.5%61.1%
LFMDLifeMD, Inc.LTM Mar 2026$172.43M USD-5.1%+4.7%78.6%
KMTSKestra Medical Technologies, Ltd.LTM Jan 2026$165.19M USD+100.5%—197.3%
BBNXBeta Bionics, Inc.LTM Mar 2026$102.76M USD+61.1%+40.3%93.2%
ATAIAtai Beckley Inc.LTM Jun 2026$71.6M USD+52.9%-10.9%1600.6%
IMTXImmatics N.V.LTM Mar 2026€53.63M EUR+14.4%+12.3%143.8%
NKTRNektar TherapeuticsLTM Jun 2026$53.31M USD-31.2%-9.4%97.7%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$44.15M USD+49.3%+72.0%2318.8%
PLSEPulse Biosciences, Inc.LTM Jun 2026$30.9M USD-1.8%+7.2%2607.6%
Peer median (excluding PLSE) —+10.3%+9.5%95.4%

Competitors are the stored peer set for PLSE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.42M700K00350K
Cost of Revenue1.97M11.94M1.21M01.61M
Gross Profit(550K)(11.24M)(1.21M)0(1.26M)
Gross Margin-38.8%-1606.3%——-360.0%
Research & Development28.64M20.84M27.8M32.34M44.72M
Selling, General & Admin33.82M25.97M15.78M23.92M32.03M
Operating Expenses62.46M46.81M42.37M56.26M75.68M
Depreciation & Amortization1.15M1.36M1.21M1.18M1.07M
EBITDA(62.51M)(57.15M)(39.9M)(52.41M)(71.71M)
EBITDA Margin-4408.6%-8164.3%——-20488.6%
Operating Income(63.01M)(58.06M)(43.57M)(56.26M)(76.94M)
Operating Margin-4443.9%-8293.9%——-21982.6%
Interest Income002.46M2.67M4.21M
Interest Expense646K448K1.1M00
Other Income / Expenses(646K)(448K)1.36M2.67M4.16M
Income Before Tax(63.66M)(58.51M)(42.21M)(53.59M)(72.78M)
Pre-Tax Margin-4489.4%-8357.9%——-20794.6%
Income Tax Expense00000
Net Income(63.66M)(58.51M)(42.21M)(53.59M)(72.78M)
Net Margin-4489.4%-8357.9%——-20794.6%
EPS (Basic)(2.28)(1.72)(0.88)(0.92)(1.08)
EPS (Diluted)(2.28)(1.72)(0.88)(0.92)(1.08)
Weighted Avg Shares27.96M33.94M48.04M58.4M67.4M
Weighted Avg Shares (Diluted)27.96M33.94M48.04M58.4M67.4M

Pulse Biosciences, Inc.

NASDAQ:PLSE

Intrinsic Alpha fair value

Locked

Current Price

$45.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.